Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)WithdrawnNCT05950113
What this trial is testing

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Jonsson Comprehensive Cancer Center
Very early researchActive Not RecruitingNCT05302648
What this trial is testing

To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM

Who this might be right for
Multiple Myeloma
Hrain Biotechnology Co., Ltd. 18
Large-scale testing (Phase 3)Study completedNCT01102426
What this trial is testing

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
PharmaMar 255
Testing effectiveness (Phase 2)Looking for participantsNCT06297226
What this trial is testing

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 230
Testing effectiveness (Phase 2)Looking for participantsNCT06103838
What this trial is testing

18F-Fluciclovine PET/CT in Multiple Myeloma

Who this might be right for
Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Study completedNCT02477215
What this trial is testing

Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Parameswaran Hari 38
Early research (Phase 1)Active Not RecruitingNCT06215118
What this trial is testing

Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Who this might be right for
Multiple Myeloma
Pfizer 100
Testing effectiveness (Phase 2)Study completedNCT01159574
What this trial is testing

Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma

Who this might be right for
Multiple Myeloma
Weill Medical College of Cornell University 121
Testing effectiveness (Phase 2)Study completedNCT00256880
What this trial is testing

Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma

Who this might be right for
Carcinoma, Renal Cell
GlaxoSmithKline 100
Testing effectiveness (Phase 2)Study completedNCT01166113
What this trial is testing

Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide

Who this might be right for
Multiple Myeloma
Fondazione EMN Italy Onlus 67
Early research (Phase 1)Looking for participantsNCT05927571
What this trial is testing

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Genentech, Inc. 120
Early research (Phase 1)Study completedNCT05227144
What this trial is testing

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
ORIC Pharmaceuticals 31
Early research (Phase 1)Study completedNCT00005634
What this trial is testing

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+3 more
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Study completedNCT05014412
What this trial is testing

Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

Who this might be right for
Multiple Myeloma
Pfizer 86
Large-scale testing (Phase 3)Ended earlyNCT03151811
What this trial is testing

Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

Who this might be right for
Multiple Myeloma
Oncopeptides AB 495
Early research (Phase 1)Study completedNCT03106428
What this trial is testing

A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

Who this might be right for
Acute Myeloid LeukemiaMultiple MyelomaDiffuse Large B-cell Lymphoma
MedImmune LLC 67
Large-scale testing (Phase 3)Not Yet RecruitingNCT07569757
What this trial is testing

Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 260
Testing effectiveness (Phase 2)WithdrawnNCT01101412
What this trial is testing

Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies

Who this might be right for
Chronic Myeloproliferative DisordersInfectionLeukemia+6 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT01319422
What this trial is testing

Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Yale University 40
Early research (Phase 1)Ended earlyNCT04036461
What this trial is testing

CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 47
Next Page